Investors to Join MoonLake Immunotherapeutics Class Action for Alleged Securities Fraud by December 2025

Overview of MoonLake Immunotherapeutics' Class Action Lawsuit

Investors in MoonLake Immunotherapeutics (NASDAQ: MLTX) have been notified by Levi & Korsinsky, LLP about an upcoming class action lawsuit concerning alleged securities fraud. This legal action pertains specifically to losses incurred between March 10, 2024, and September 29, 2025. As a result of these allegations, investors are urged to understand their rights and options before the deadline of December 15, 2025.

Details of the Allegations

The lawsuit against MoonLake centers around claims that the company’s executives made misleading statements and omitted critical information about their key drug candidate. The complaint asserts that its only drug candidate, SLK, did not possess the purported benefits over its competitor, BIMZELX, in the treatment of inflammatory conditions. Specifically, the lawsuit claims:

1. Both SLK and BIMZELX target the same inflammatory cytokines, IL-17A and IL-17F.
2. The Nanobody structure of SLK, touted as a superior alternative, has not demonstrated clear clinical advantages over traditional monoclonal antibodies.
3. Assertions that this distinct structure allowed better tissue penetration failed to translate into actual clinical efficacy.
4. Consequently, the positive statements made about SLK's potential were built on insufficient grounds.

This legal action could provide a pathway for affected investors to recover losses they experienced within the designated timeframe.

Next Steps for Affected Investors

Investors who have experienced losses due to the alleged fraud are encouraged to take action. Levi & Korsinsky offers a platform for investors to express their interest in being appointed as lead plaintiff by the court. This does not require any upfront payment or out-of-pocket expenses, emphasizing that there is no obligation to engage in this process.

Interested parties can contact Joseph E. Levi, Esq., via email at [email protected] or call (212) 363-7500. Additionally, more information can be accessed through the official submission link provided by the firm to facilitate an easier understanding of one’s rights and options in this circumstance.

Why Levi & Korsinsky?

Levi & Korsinsky, LLP is a reputable legal firm with extensive experience in securities litigation, boasting a track record that spans over two decades. The firm has successfully secured substantial settlements for shareholders in previous cases, with more than 70 professionals dedicated to serving clients in complex legal matters. In fact, for seven consecutive years, they have been recognized among the top securities litigation firms in the United States by the ISS Securities Class Action Services report, underscoring their prestige and expertise in this field.

Conclusion

As the class action lawsuit against MoonLake Immunotherapeutics progresses, it remains essential for investors to stay informed and proactive. With the deadline approaching, affected investors should connect with Levi & Korsinsky to discuss potential participation in the class action lawsuit, ensuring their rights are protected and that they have the option to pursue compensation for their losses.